UPDATE: Credit Suisse On Atai Life Sciences Outperform Initiation: Firm Sees Diversified NeuroPsych Platform With 'Material Exposure To Psychedelics' With Co. Programs Covering Depression, Substance Use Disorder, Cognitive Impairment, Anxiety, & PTSD